crohn's disease and glp-1 Agonists Disease: Risks and Management The Potential for GLP-1s in
Description
Effect of glepaglutide, a long-acting glucagon-like peptide-2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial
doi: 10.1152/nips.01442.2003
Current and potential therapeutic targets of glucagon-like peptide-2
[5] Any insulin dose adjustments should only be made under clinical supervision
